MedTrace Logo

Evaluation of Antiproliferative Effects of Arimidex in Ductal Lavage Fluid in Patients With Breast Cancer

NCT01207635 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 42

Last updated 2012-07-30

No results posted yet for this study

Summary

The goal of this study is to evaluate antiproliferative effects of Arimidex in ductal lavage fluids of Breast Cancer patients.

Breast cancer is the leading cause of cancer incidence and the second leading cause of cancer mortality in women. Breast duct fluid provide biomarkers to aid in risk assessment of developing breast cancer.

Conditions

Interventions

PROCEDURE

Ductal Lavage Fluid Collection

Procedure of inserting a small catheter into the ductal openings in the nipple and washing out cells from inside the duct.

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Banu Arun, MD · UT MD Anderson Cancer Center

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-11-30
Primary Completion
2006-01-31
Completion
2006-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01207635 on ClinicalTrials.gov